Reinnervation and Neuromuscular Transmission in ALS (RANTAL)

University of Aarhus

Status: Enrolling

Conditions: Amyotrophic Lateral Sclerosis

Treatments: Other: Observational study

Study type: Observational

Funder types: Other

Identifiers

NCT06219759

8340

1-10-72-153-23 (Other Identifier)

Details and patient eligibility

About

The aim of this study is to describe the changes in the neuromuscular connection in patients with amyotrophic lateral sclerosis (ALS). The study consist of three substudies that have the following main hypothesis:

1. that ALS patients do not demonstrate equal capacity for muscle reinnervation and that reinnervation preserves muscle function and thereby slows down progression.
2. that blood concentrations of c-terminal agrin fragment (bCAF) reflect neuromuscular transmission deficiency and that blood concentration of neural cell adhesion molecule reflects degree of muscle denervation in patients.
3. that ALS patients with decrement when examined with repetitive nerve stimulation have more physical fatigue, slower progression, higher degree of reinnervation and higher bCAF compared to ALS patients without decrement.

There will be 3 inclusion groups.

1. patients referred for neurophysiological examination on suspicion of motor neuron disease.
2. healthy controls
3. disease control: patients with another motor neuron disease with slow progression.

All participants will be invited for at least 1 visit (baseline). If participants in group 1 eventually receive the diagnosis of ALS they will be invited for 2 additional visits 4 og 8 months after baseline visit, respectively.

Examinations will consist of:

• nerve conduction study
• repetitive nerve stimulation (except for healthy controls) to examine impairment of the neuromuscular connection.
• motor unit number estimation with MScanFit to estimate number and size of motor units.
• ultrasound examination of muscles to measure size and condition of muscles.
• questionnaires on fatigue and functional status.
• blood sample for measurement of specialized analysis (c-terminal agrin fragment and neural cell adhesion molecule) and routine analysis (liver and kidney function as well as neurofilament light chain)
• muscle strength assessment manually and by dynamometer to follow progression of muscle weakness
• bioelectrical impedance measurement to follow the overall body composition.

Enrollment: 120 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Referred to clinical neurophysiological examination on suspicion of motor neuron disease or diagnosed with ALS according to Gold Coast criteria within the last 3 months.
• Age ≥18 years old
• Able and willing to provide informed consent

Exclusion criteria

• Former central or peripheral nervous system disease
• Diabetes
• Electrophysiological signs of polyneuropathy at baseline visit
• Pacemaker
• Pregnancy

For disease controls the exclusion criteria are the same, but the inclusion criteria:

• Diagnosed with disease with slow, progressive loss of motor neurons
• Age ≥18 years old
• Able and willing to provide informed consent

Trial design

120 participants in 4 patient groups

ALS patients

Description:

Patients enrolled prior to determination of diagnosis on referral to neurophysiological examination. When the diagnosis is later established they get categorized as ALS patients. ALS patients with recent diagnosis might also be included directly.

Treatment:

Other: Observational study

ALS mimic disease patients

Description:

Patients enrolled prior to determination of diagnosis on referral to neurophysiological examination. When diagnosis is later established and the diagnosis is NOT ALS they get categorized as ALS mimic disease patients.

Treatment:

Other: Observational study

Healthy controls

Description:

Healthy controls.

Treatment:

Other: Observational study

Disease controls

Description:

Patients with another motor neuron disease than ALS with slow progression.

Treatment:

Other: Observational study